Bots and AI are dominating Polymarket by exploiting mispriced odds and latency, leaving human traders struggling to compete.
21h
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback